LFWD · XBRL financial data

Lifeward financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (LFWD's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025†Dec 31, 2025
Revenue	4,393	5,966	5,511	13,854	25,663	22,034
Revenue from contracts with customers	330	432	352	435	1,700	1,400
Cost of revenue	2,204	3,063	3,606	9,401	17,447	13,606
Gross profit	2,189	2,903	1,905	4,453	8,216	8,428
Research and development	3,459	2,939	4,031	4,148	4,625	3,249
General and administrative	4,980	5,626	7,134	9,995	5,195	8,195
Total operating expenses	14,193	15,558	21,007	28,065	37,563	28,102
Operating income (loss)	(12,004)	(12,655)	(19,102)	(23,612)	(29,347)	(19,674)
Interest expense	907	0	—	—	—	—
Income tax expense (benefit)	51	94	467	(12)	43	(55)
Net income (loss)	(12,976)	(12,736)	(19,569)	(22,133)	(28,942)	(19,914)
Earnings per share, basic USD per share	(0.82)	(0.27)	(0.31)	(0.37)	(3.33)	(17.16)
Earnings per share, diluted USD per share	(0.82)	(0.27)	(0.31)	(0.37)	(3.33)	(17.16)
Weighted average shares, basic thousands of shares	15,765	47,936	62,379	59,719	8,691	1,161
Weighted average shares, diluted thousands of shares	15,765	47,936	62,379	59,719	8,691	1,161

† Share count changed about 1/7 in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal years (LFWD's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025†Dec 31, 2025
Cash and cash equivalents	20,350	88,337	67,896	28,083	6,746	2,169
Accounts receivable	684	585	1,036	3,120	6,004	6,138
Inventory	3,542	2,989	2,929	5,653	6,723	5,732
Prepaid and other current assets	672	610	649	2,366	1,624	1,528
Total current assets	25,248	92,521	72,510	39,222	21,294	15,807
Property and equipment, net	437	284	196	1,262	867	585
Right-of-use asset	1,349	881	836	1,861	548	1,544
Goodwill	—	—	0	7,538	7,538	4,755
Total assets	28,067	94,750	74,236	63,192	30,487	22,900
Accounts payable	2,268	1,384	1,950	5,069	5,022	5,590
Total current liabilities	4,668	4,038	4,782	11,795	10,225	12,039
Lease liability, non-current	923	418	333	607	22	1,159
Total liabilities	6,293	5,367	6,071	16,682	11,638	14,492
Accumulated deficit	(181,445)	(194,181)	(213,750)	(235,883)	(264,825)	(284,739)
Total stockholders' equity	21,774	89,383	68,165	46,510	18,849	8,408
Total liabilities and equity	28,067	94,750	74,236	63,192	30,487	22,900
Common shares outstanding (cover page) thousands of shares	33,445	62,508	59,480	59,480	10,630	1,528

† Share count changed about 1/7 in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal years (LFWD's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025†Dec 31, 2025
Net income (loss)	(12,976)	(12,736)	(19,569)	(22,133)	(28,942)	(19,914)
Stock-based compensation	749	833	993	1,328	1,281	743
Net cash from operating activities	(12,589)	(11,469)	(17,891)	(20,667)	(21,718)	(16,826)
Purchases of property and equipment	73	47	25	81	0	16
Net cash from investing activities	(73)	(47)	(25)	(18,149)	0	(16)
Proceeds from long-term debt	392	0	0	—	—	—
Repayments of long-term debt	6,965	0	0	—	—	—
Net cash from financing activities	16,724	79,512	(2,500)	(992)	0	12,203
Net change in cash	4,062	67,996	(20,495)	(39,763)	(21,684)	(4,529)

† Share count changed about 1/7 in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

SIC 3842 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3842 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Lifeward	9,448	6,623	(6,005)*	2.8M	1.6 quarters	Q2 FY26 10-QJun 30, 2026
Co-Diagnostics	3,650	166	(7,153)*	6.3M	0.5 quarters	Q2 FY26 10-QJun 30, 2026
Mountain Crest Acquisition Corp. V	18	not reported	(79)*	2.9M	0.2 quarters	Q2 FY26 10-QJun 30, 2026
Guided Therapeutics	12	0	(319)*	96.5M	0.0 quarters	Q2 FY26 10-QJun 30, 2026
Medinotec	2,584	3,201	108*	11.8M	—	Q2 FY27 10-QAug 31, 2026
Nexgel	1,706	3,686	(2,197)*	9.7M	0.8 quarters	Q2 FY26 10-QJun 30, 2026
Lyra Therapeutics	15,893	7*	(6,066)*	1.8M	2.6 quarters	Q4 FY25 10-KDec 31, 2025
Semler Scientific	10,176	7,491	(32,950)*	15.2M	0.3 quarters	Q3 FY25 10-QSep 30, 2025
Intelligent Bio Solutions	3,992	1,146*	(3,182)*	3.0M	1.3 quarters	Q4 FY26 10-KJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.